文献速递临床试验与 GCP流行病学与生物统计

高龄高血压患者减药策略与常规照护对短期血压控制的随机对照试验

Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

OPTIMISE 研究为在英格兰 69 家基层诊所开展的随机、非盲、非劣效试验,纳入 80 岁及以上、收缩压低于 150 mm Hg 且使用至少 2 种降压药的 569 例患者。12 周随访时,减药组与常规照护组收缩压低于 150 mm Hg 的比例分别为 86.4% 与 87.7%,达到非劣效;减药组平均收缩压较对照组高 3.4 mm Hg。

要点

  • 80 岁及以上多药降压患者中,减药策略在 12 周收缩压控制上非劣于常规照护。
  • 减药组 66.3% 患者在 12 周时维持减药,平均收缩压较对照组高 3.4 mm Hg。
  • 严重不良事件两组差异无统计学意义,但长期临床结局仍需进一步研究。

核心结论

  • 在 80 岁及以上使用多种降压药的患者中,减药策略在 12 周收缩压控制方面非劣于常规照护。
  • 减药与血压控制无实质性变化相关,但长期临床结局尚需进一步研究。

研究设计与样本

  • OPTIMISE 为随机、非盲、非劣效试验,在英格兰 69 家基层诊所开展。
  • 纳入 80 岁及以上、收缩压低于 150 mm Hg、使用至少 2 种降压药且经全科医生判断适合减药的患者 569 例。
  • 参与者按 1:1 随机分为减药策略组(移除 1 种药物,n=282)或常规照护组(n=287),随访 12 周。

主要发现

  • 12 周时减药组 229 例(86.4%)、对照组 236 例(87.7%)收缩压低于 150 mm Hg,校正 RR 为 0.98(97.5% 单侧 CI,0.92 至 ∞)。
  • 7 个预设次要终点中 5 个无显著差异。
  • 12 周时 187 例(66.3%)参与者维持减药。
  • 减药组平均收缩压较对照组高 3.4 mm Hg(95% CI,1.1 至 5.8 mm Hg)。
  • 减药组 12 例(4.3%)、对照组 7 例(2.4%)报告至少 1 次严重不良事件,校正 RR 为 1.72(95% CI,0.7 至 4.3)。

关键数值与推荐

  • 主要终点为 12 周随访时收缩压低于 150 mm Hg。
  • 预设非劣效界值为相对危险度(RR)0.90。

临床怎么用

  • 对 80 岁及以上、收缩压低于 150 mm Hg 且多药降压的患者,可考虑在密切监测下减少 1 种降压药。
  • 减药后应关注收缩压平均升高约 3.4 mm Hg 及严重不良事件风险。

局限性

  • 研究为非盲设计。
  • 随访仅 12 周,长期临床结局不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and multimorbidity when the benefits of continued treatment may not outweigh the harms. OBJECTIVE: This study aimed to establish whether antihypertensive medication reduction is possible without significant changes in systolic blood pressure control or adverse events during 12-week follow-up. DESIGN, SETTING, AND PARTICIPANTS: The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites in England. Participants, whose primary care physician considered them appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2 antihypertensive medications were included. Participants enrolled between April 2017 and September 2018 and underwent follow-up until January 2019. INTERVENTIONS: Participants were randomized (1:1 ratio) to a strategy of antihypertensive medication reduction (removal of 1 drug [intervention], n = 282) or usual care (control, n = 287), in which no medication changes were mandated. MAIN OUTCOMES AND MEASURES: The primary outcome was systolic blood pressure lower than 150 mm Hg at 12-week follow-up. The prespecified noninferiority margin was a relative risk (RR) of 0.90. Secondary outcomes included the proportion of participants maintaining medication reduction and differences in blood pressure, frailty, quality of life, adverse effects, and serious adverse events. RESULTS: Among 569 patients randomized (mean age, 84.8 years; 276 [48.5%] women; median of 2 antihypertensive medications prescribed at baseline), 534 (93.8%) completed the trial. Overall, 229 (86.4%) patients in the intervention group and 236 (87.7%) patients in the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks (adjusted RR, 0.98 [97.5% 1-sided CI, 0.92 to ∞]). Of 7 prespecified secondary end points, 5 showed no significant difference. Medication reduction was sustained in 187 (66.3%) participants at 12 weeks. Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.8 mm Hg) higher in the intervention group compared with the control group. Twelve (4.3%) participants in the intervention group and 7 (2.4%) in the control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]). CONCLUSIONS AND RELEVANCE: Among older patients treated with multiple antihypertensive medications, a strategy of medication reduction, compared with usual care, was noninferior with regard to systolic blood pressure control at 12 weeks. The findings suggest antihypertensive medication reduction in some older patients with hypertension is not associated with substantial change in blood pressure control, although further research is needed to understand long-term clinical outcomes. TRIAL REGISTRATION: EudraCT Identifier: 2016-004236-38; ISRCTN identifier: 97503221.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sheppard JP, Burt J, Lown M, et al. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020. PMID: 32453368. doi:10.1001/jama.2020.4871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。